Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. nature reviews immunology 
3. review articles 
4. article
•  Review Article
•  Published: 16 November 2012


Eosinophils: changing
perspectives in health and
disease
•  Helene F. Rosenberg
1,
•  Kimberly D. Dyer1 &
•  Paul S. Foster2 
Nature Reviews Immunology volume 13, pages 9–22 (2013)Cite this
article
•  40k Accesses
•  823 Citations
•  20 Altmetric
•  Metrics details
Subjects
•  Allergy
•  Granulocytes
•  Infection
•  Innate immunity
Key Points
•  Eosinophils have been traditionally perceived as terminally
differentiated cytotoxic effector cells. Recent studies have
provided a more sophisticated understanding of eosinophil
effector functions and a more nuanced view of their
contributions to the pathogenesis of various diseases,
including asthma and respiratory allergies, eosinophilic
gastrointestinal diseases, hypereosinophilic syndromes and
parasitic infection.


•  Eosinophils are granulocytes that develop in the bone marrow
from pluripotent progenitors in response to cytokines, such as
interleukin-5 (IL-5), IL-3 and granulocyte–macrophage
colony-stimulating factor (GM-CSF). Mature eosinophils are
released into the peripheral blood and enter tissues in
response to cooperative signalling between IL-5 and eotaxin
family chemokines.
•  Eosinophils in peripheral blood and tissues are uniquely
identified by their bilobed nuclei, their large specific granules
that store cytokines, cationic proteins and enzymes, and their
expression of the IL-5 receptor and CC-chemokine receptor 3
(CCR3). In addition, the receptors sialic acid-binding
immunoglobulin-like lectin 8 (SIGLEC-8) and SIGLEC-F are
expressed by human and mouse eosinophils, respectively.
•  IL-5 has a central and profound role in all aspects of
eosinophil development, activation and survival. IL-5 is
produced by T helper 2 (TH2) cells, and more recently the
contributions of the epithelium-derived innate cytokines
thymic stromal lymphopoietin (TSLP), IL-25 and IL-33 in
promoting eosinophilia via the induction of IL-5 have also
been recognized.
•  Although eosinophil responses are influenced by cytokines
produced by T cells, eosinophils in turn modulate the
functions of B and T cells. Eosinophils also communicate with
a range of innate immune cells (such as mast cells, dendritic
cells, macrophages and neutrophils). Eosinophils serve to
bridge innate and adaptive immunity by regulating the
production of chemoattractants and cytokines (including CC-
chemokine ligand 17 (CCL17), CCL22, a proliferation-
inducing ligand (APRIL) and IL-6) and via antigen
presentation.
•  Both successful and unsuccessful attempts to target
eosinophils have yielded remarkable insights into their
contribution to disease pathogenesis. Many eosinophil-
associated inflammatory conditions have been shown to be
heterogeneous in nature. As such, successful therapeutic
strategies will depend on the correlation of disease activity


with dysregulated eosinophil function as well as the
identification of the crucial molecules that regulate eosinophil
accumulation in the affected tissues.
Abstract
Eosinophils have been traditionally perceived as terminally
differentiated cytotoxic effector cells. Recent studies have
profoundly altered this simplistic view of eosinophils and their
function. New insights into the molecular pathways that control the
development, trafficking and degranulation of eosinophils have
improved our understanding of the immunomodulatory functions of
these cells and their roles in promoting homeostasis. Likewise,
recent developments have generated a more sophisticated view of
how eosinophils contribute to the pathogenesis of different diseases,
including asthma and primary hypereosinophilic syndromes, and
have also provided us with a more complete appreciation of the
activities of these cells during parasitic infection.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
 Access through your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Learn more
Buy this article


•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions
•  Read our FAQs
•  Contact customer support
Figure 1: The eosinophil.
[image]
Figure 2: Cellular features of eosinophils.
[image]
Figure 3: Eosinophils modulate the function of other
leukocytes.
[image]
Similar content being viewed by others
[image]
Spatial adaptation of eosinophils and their emerging
roles in homeostasis, infection and disease
Article 09 July 2024
[image]
Stress-free single-cell transcriptomic profiling and
functional genomics of murine eosinophils
Article 19 March 2024
[image]


Active eosinophils regulate host defence and immune
responses in colitis
Article Open access 12 December 2022
References
1. Steinbach, K. H. et al. Estimation of kinetic parameters of
neutrophilic, eosinophilic, and basophilic granulocytes in
human blood. Blut 39, 27–38 (1979).
Article  CAS  PubMed  Google Scholar 
2. Lamousé-Smith, E. S. & Furuta, G. T. Eosinophils in the
gastrointestinal tract. Curr. Gastroenterol. Rep. 8, 390–395
(2006).
Article  PubMed  Google Scholar 
3. Hogan, S. P. et al. Eosinophils: biological properties and role
in health and disease. Clin. Exp. Allergy 38, 709–750 (2008).
Article  CAS  PubMed  Google Scholar 
4. Blanchard, C. & Rothenberg, M. E. Biology of the eosinophil.
Adv. Immunol. 101, 81–121 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
5. Foster, P. S. et al. Elemental signals regulating eosinophil
accumulation in the lung. Immunol. Rev. 179, 173–181
(2001).
Article  CAS  PubMed  Google Scholar 
6. Fabre, V. et al. Eosinophil deficiency compromises parasite
survival in chronic nematode infection. J. Immunol. 182,
1577–1583 (2009). This study demonstrated that, in the
absence of eosinophils, muscle-residentlarvae of the
parasite Trichinella spiralis died in large numbers in an
infected mouse model. These results suggest that, among


other possibilities, eosinophils are recruited to sustain
rather than eliminate parasitic infection, a potentially
interesting reversal of the traditional view.
Article  CAS  PubMed  Google Scholar 
7. Gebreselassie, N. G. et al. Eosinophils preserve parasitic
nematode larvae by regulating local immunity. J. Immunol.
188, 417–425 (2012).
Article  CAS  PubMed  Google Scholar 
8. Wegmann, M. Targeting eosinophil biology in asthma
therapy. Am. J. Respir. Cell. Mol. Biol. 45, 667–674 (2011).
Article  CAS  PubMed  Google Scholar 
9. Jacobsen, E. A., Ochkur, S. I., Lee, N. A. & Lee, J. J.
Eosinophils and asthma. Curr. Allergy Asthma Rep. 7, 18–26
(2007).
Article  CAS  PubMed  Google Scholar 
10. Yu, C. et al. Targeted deletion of a high-affinity GATA-
binding site in the GATA-1 promoter leads to selective loss of
the eosinophil lineage in vivo. J. Exp. Med. 195, 1387–1395
(2002). This paper describes the serendipitous creation of
the ΔdblGATA eosinophil-deficient mouse model.
Article  CAS  PubMed  PubMed Central  Google Scholar 
11. Lee, J. J. et al. Defining a link with asthma in mice
congenitally deficient in eosinophils. Science 305, 1773–1776
(2004). In this paper, the authors describe the creation of
the TgPHIL eosinophil-deficient mouse model using a
cytosuicide approach and demonstrate the role of
eosinophils in inflammation and tissue remodelling in
allergic airway disease.
Article  CAS  PubMed  Google Scholar 
12. Lee, J. J. et al. Human versus mouse eosinophils: “that which


we call an eosinophil, by any other name would stain as red”.
J. Allergy Clin. Immunol. 130, 572–584 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
13. Shamri, R., Xenakis, J. J. & Spencer, L. A. Eosinophils in
innate immunity: an evolving story. Cell Tissue Res. 343, 57–
83 (2011).
Article  PubMed  Google Scholar 
14. Mould, A., Matthaei, K., Young, I. & Foster, P. Relationship
between interleukin-5 and eotaxin in regulating blood and
tissue eosinophilia in mice. J. Clin. Invest. 99, 1064–1071
(1997). The findings of this study demonstrate the
interactions between IL-5 and CCL11 in promoting
eosinophil release from the bone marrow and eosinophil
homing to tissues.
Article  CAS  PubMed  PubMed Central  Google Scholar 
15. Collins, P. D., Marleau, S., Griffiths-Johnson, D. A., Jose, P. J.
& Williams, T. J. Cooperation between interleukin-5 and the
chemokine eotaxin to induce eosinophil accumulation in vivo.
J. Exp. Med. 182, 1169–1174 (1995).
Article  CAS  PubMed  Google Scholar 
16. Wong, C. K., Hu, S., Cheung, P. F. & Lam, C. W. Thymic
stromal lymphopoietin induces chemotactic and prosurvival
effects in eosinophils: implications in allergic inflammation.
Am. J. Respir. Cell. Mol. Biol. 43, 305–315 (2010).
Article  CAS  PubMed  Google Scholar 
17. Moro, K. et al. Innate production of TH2 cytokines by adipose
tissue-associated c- Kit+Sca-1+ lymphoid cells. Nature 463,
540–544 (2010).
CAS  PubMed  Google Scholar 
18. Neill, D. R. et al. Nuocytes represent a new innate effector


leukocyte that mediates type-2 immunity. Nature 464, 1367–
1370 (2010). As shown in this manuscript, stimulation
with IL-25 and IL-33 causes a newly discovered innate
effector leukocyte population to expand and to release
the eosinophil-activating cytokines IL-5 and IL-13.
Article  CAS  PubMed  PubMed Central  Google Scholar 
19. Ikutani, M. et al. Identification of innate IL-5-producing cells
and their role in lung eosinophil regulation and antitumor
immunity. J. Immunol. 188, 703–713 (2012).
Article  CAS  PubMed  Google Scholar 
20. Corrigan, C. J. et al. Allergen-induced expression of IL-25 and
IL-25 receptor in atopic asthmatic airways and late-phase
cutaneous responses. J. Allergy Clin. Immunol. 128, 116–124
(2011).
Article  CAS  PubMed  Google Scholar 
21. Terrier, B. et al. Interleukin-25: a cytokine linking eosinophils
and adaptive immunity in Churg-Strauss syndrome. Blood
116, 4523–4531 (2010).
Article  CAS  PubMed  Google Scholar 
22. Mirchandani, A. S., Salmond, R. J. & Liew, F. Y.
Interleukin-33 and the function of innate lymphoid cells.
Trends Immunol. 33, 389–396 (2012).
Article  CAS  PubMed  Google Scholar 
23. Cherry, W. B., Yoon, J., Bartemes, K. R., Iijima, K. & Kita, H.
A novel IL-4 family cytokine, IL-33, potently activates human
eosinophils. J. Allergy Clin. Immunol. 121, 1484–1490 (2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
24. Matsuba-Kitamura, S. et al. Contribution of IL-33 to induction
and augmentation of experimental allergic conjunctivitis. Int.
Immunol. 22, 479–489 (2010).


Article  CAS  PubMed  Google Scholar 
25. Mjösberg, J. M. et al. Human IL-25- and IL-33-responsive type
2 innate lymphoid cells are defined by expression of CRTH2
and CD161. Nature Immunol. 12, 1055–1062 (2011).
Article  CAS  Google Scholar 
26. Li, Y. et al. Silencing IL-23 expression by small hairpin RNA
protects against asthma in mice. Exp. Mol. Med. 43, 197–204
(2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
27. Peng, J., Yang, X. O., Chang, S. H., Yang, J. & Dong, C. IL-23
signaling enhances Th2 polarization and regulates allergic
airway inflammation. Cell Res. 20, 62–71 (2010).
Article  CAS  PubMed  Google Scholar 
28. Szymczak, W. A., Sellers, R. S. & Pirofski, L. A. IL-23 dampens
theallergic response to Cryptococcus neoformans through
IL-17-independent and -dependent mechanisms. Am. J. Pathol.
180, 1547–1559 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
29. Lotfi, R., Lee, J. J. & Lotze, M. T. Eosinophilic granulocytes
and damage-associated molecular pattern molecules
(DAMPs): role in the inflammatory response within tumors. J.
Immunother. 30, 16–28 (2007). This paper is one of the first
to consider a role for endogenous DAMPs in the induction
of eosinophilic inflammation.
Article  CAS  PubMed  Google Scholar 
30. Dvorak, A. M., Estrella, P. & Ishizaka, T. Vesicular transport
of peroxidase in human eosinophilic myelocytes. Clin. Exp.
Allergy 24, 10–18 (1994).
Article  CAS  PubMed  Google Scholar 


31. Melo, R. C. et al. Human eosinophils secrete preformed,
granule-stored interleukin-4 through distinct vesicular
compartments. Traffic 6, 1047–1057 (2005).
Article  CAS  PubMed  PubMed Central  Google Scholar 
32. Spencer, L. A. et al. Cytokine receptor-mediated trafficking of
preformed IL-4 in eosinophils identifies an innate immune
mechanism of cytokine secretion. Proc. Natl Acad. Sci. USA
103, 3333–3338 (2006). This work documents the
complexity of receptor-mediated intracellular trafficking
and its contributions to piecemeal degranulation.
Article  CAS  PubMed  PubMed Central  Google Scholar 
33. Lacy, P. & Stow, J. L. Cytokine release from innate immune
cells: association with diverse membrane trafficking
pathways. Blood 118, 9–18 (2011).
Article  CAS  PubMed  Google Scholar 
34. Neves, J. S. et al. Eosinophil granules function extracellularly
as receptor-mediated secretory organelles. Proc. Natl Acad.
Sci. USA 105, 18478–18483 (2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
35. Neves, J. S. & Weller, P. F. Functional extracellular eosinophil
granules: novel implications in eosinophil immunobiology.
Curr. Opin. Immunol. 21, 694–699 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
36. Walsh, G. M. Antagonism of eosinophil accumulation in
asthma. Recent Pat. Inflamm. Allergy Drug Discov. 4, 210–213
(2010).
Article  CAS  PubMed  Google Scholar 
37. Mackenzie, J., Mattes, J., Dent, L. & Foster, P. Eosinophils
promote allergic disease of the lung by regulating CD4+ Th2
lymphocyte function. J. Immunol. 167, 3146–3155 (2001).


Article  CAS  PubMed  Google Scholar 
38. Mattes, J. et al. Intrinsic defect in T cell production of
interleukin (IL)-13 in the absence of both IL-5 and eotaxin
precludes the development of eosinophilia and airways
hyperreactivity in experimental asthma. J. Exp. Med. 195,
1433–1444 (2002).
Article  CAS  PubMed  PubMed Central  Google Scholar 
39. Wang, H. B., Ghiran, I., Matthaei, K. & Weller, P. F. Airway
eosinophils: allergic inflammation recruited professional
antigen-presenting cells. J. Immunol. 179, 7585–7592 (2007).
Article  CAS  PubMed  Google Scholar 
40. Jacobsen, E. A. et al. Allergic pulmonary inflammation in
mice is dependent on eosinophil-induced recruitment of
effector T cells. J. Exp. Med. 205, 699–710 (2008). An
intriguing manuscript in which the authors use the
eosinophil-deficient TgPHIL mouse model to demonstrate
eosinophil-dependent recruitment of effector T cells to
the lungs of allergen-challenged mice.
Article  CAS  PubMed  PubMed Central  Google Scholar 
41. Jacobsen, E. A., Zellner, K. R., Colbert, D., Lee, N. A. & Lee, J.
J. Eosinophils regulate dendritic cells and Th2 pulmonary
immune responses following allergen provocation. J.
Immunol. 87, 6059–6068 (2011).
Article  Google Scholar 
42. Spencer, L. A. et al. Human eosinophils constitutively express
multiple Th1,Th2 and immunoregulatory cytokines that are
secreted rapidly and differentially. J. Leukoc. Biol. 85, 117–
123 (2009).
Article  CAS  PubMed  Google Scholar 
43. Wang, H. B. & Weller, P. F. Pivotal advance: eosinophils
mediate early alum adjuvant-elicited B cell priming and IgM


production. J. Leukoc. Biol. 83, 817–821 (2008).
Article  CAS  PubMed  Google Scholar 
44. Chu, V. T. et al. Eosinophils are required for the maintenance
of plasma cells in the bone marrow. Nature Immunol. 12, 151–
159 (2011). In this study, the authors show that
eosinophils and plasma cells colocalize in mouse bone
marrow and that plasma cell survival is supported by the
eosinophil secretory mediators APRIL and IL-6.
Article  CAS  Google Scholar 
45. Chu, V. T. & Berek, C. Immunization induces activation of
bone marrow eosinophil required for plasma cell survival.
Eur. J. Immunol. 42, 130–137 (2012).
Article  CAS  PubMed  Google Scholar 
46. Voehringer, D., van Rooijen, N. & Locksley, R. M. Eosinophils
develop in distinct stages and are recruited to peripheral sites
by alternatively activated macrophages. J. Leukoc. Biol. 81,
1434–1444 (2007).
Article  CAS  PubMed  Google Scholar 
47. Dasgupta, P. & Keegan, A. D. Contribution of alternatively
activated macrophages to allergic lung inflammation: a tale of
mice and men. J. Innate Immun. 4, 478–488 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
48. Falcone, F. H. et al. Brugia malayi homolog of macrophage
migration inhibitory factor reveals an important link between
macrophages and eosinophil recruitment during nematode
infection. J. Immunol. 167, 5348–5354 (2001).
Article  CAS  PubMed  Google Scholar 
49. Webb, D. et al. Expression of the Ym2 lectin-binding protein
is dependent on interleukin (IL)-4 and IL-13 signal
transduction: identification of a novel allergy-associated


protein. J. Biol. Chem. 276, 41969–41976 (2001).
Article  CAS  PubMed  Google Scholar 
50. Wu, D. et al. Eosinophils sustain adipose alternatively
activated macrophages associated with glucose homeostasis.
Science 332, 243–247 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
51. Lotfi, R. & Lotze, M. Eosinophils induce DC maturation,
regulating immunity. J. Leukoc. Biol. 83, 456–460 (2008).
Article  CAS  PubMed  Google Scholar 
52. Yang, D. et al. Eosinophil-derived neurotoxin (EDN), an
antimicrobial protein with chemotactic activities for dendritic
cells. Blood. 102, 3396–3403 (2003).
Article  CAS  PubMed  Google Scholar 
53. Yang, D. et al. Eosinophil-derived neurotoxin acts as an
alarmin to activate the TLR2–MyD88 signal pathway in
dendritic cells and enhances Th2 immune responses. J. Exp.
Med. 205, 79–90 (2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
54. Elishmereni, M. et al. Physical interactions between mast cells
and eosinophils: a novel mechanism enhancing eosinophil
survival in vitro. Allergy 66, 376–385 (2011).
Article  CAS  PubMed  Google Scholar 
55. Pearce, E. J. & MacDonald, A. S. The immunobiology of
schistosomiasis. Nature Rev. Immunol. 2, 499–511 (2002).
Article  CAS  Google Scholar 
56. Sher, A., Coffman, R. L., Hieny, S. & Cheever, A. W. Ablation
of eosinophil and IgE responses with anti-IL-5 or anti-IL-4
antibodies fails to affect immunity against Schistosoma


mansoni in the mouse. J. Immunol. 145, 3911–3916 (1990).
CAS  PubMed  Google Scholar 
57. Swartz, J. M. et al. Schistosoma mansoni infection in
eosinophil lineage-ablated mice. Blood 108, 2420–2427
(2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
58. Sasaki, O., Sugaya, H., Ishida, K. & Yoshimura, K. Ablation of
eosinophils with anti-IL-5 antibody enhances the survival of
intracranial worms of Angiostrongylus cantonensis in the
mouse. Parasite Immunol. 15, 349–454 (1993).
Article  CAS  PubMed  Google Scholar 
59. Rotman, H. L. et al. Strongyloides stercoralis: eosinophil-
dependent immune-mediated killing of third stage larvae in
BALB/cByJ mice. Exp. Parasitol. 82, 267–278 (1996).
Article  CAS  PubMed  Google Scholar 
60. Eriksson, J. et al. The 434(G>C) polymorphism within the
coding sequence of eosinophil cationic protein (ECP)
correlates with the natural course of Schistosoma mansoni
infection. Int. J. Parasitol. 37, 1359–1366 (2007).
Article  CAS  PubMed  Google Scholar 
61. Adu, B. et al. Polymorphisms in the RNASE3 gene are
associated with susceptibility to cerebral malaria in Ghanaian
children. PLoS ONE 6, e29465 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
62. Lehrer, R. I. et al. Antibacterial properties of eosinophil major
basic protein and eosinophil cationic protein. J. Immunol.
142, 4428–4434 (1989). This is one of the first papers to
suggest an antimicrobial role for eosinophils.
CAS  PubMed  Google Scholar 


63. Rosenberg, H. F. Recombinant human eosinophil cationic
protein: ribonuclease activity is not essential for cytotoxicity.
J. Biol. Chem. 270, 7876–7881 (1995).
Article  CAS  PubMed  Google Scholar 
64. Torrent, M., Navarro, S., Moussaoui, M., Nogués, M. V. &
Boix, E. Eosinophil cationic protein high-affinity binding to
bacteria-wall lipopolysaccharides and peptidoglycans.
Biochemistry 47, 3544–3555 (2008).
Article  CAS  PubMed  Google Scholar 
65. Yousefi, S. et al. Catapult-like release of mitochondrial DNA
by eosinophils contributes to antibacterial defense. Nature
Med. 14, 949–953 (2008).
Article  CAS  PubMed  Google Scholar 
66. von Köckritz-Blickwede, M. & Nizet, V. Innate immunity
turned inside-out: antimicrobial defense by phagocyte
extracellular traps. J. Mol. Med. 87, 775–783 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
67. Linch, S. N. et al. Mouse eosinophils possess potent
antibacterial properties in vivo. Infect. Immun. 77, 4976–4982
(2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
68. Linch, S. N. et al. IL-5 is protective during sepsis in an
eosinophil-independent manner. Am. J. Respir. Crit. Care Med.
186, 246–254 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
69. Huang, J. et al. The effects of probiotics supplementation
timing on an ovalbumin-sensitized rat model. FEMS Immunol.
Med. Microbiol. 60, 132–141 (2010).
Article  CAS  PubMed  Google Scholar 


70. Yu, J. et al. The effects of Lactobacillus rhamnosus on the
prevention of asthma in a murine model. Allergy Asthma
Immunol. Res. 2, 199–205 (2010).
Article  CAS  PubMed  PubMed Central  Google Scholar 
71. Rose, M. A., Schubert, R., Schulze, J. & Zielen, S. Follow-up of
probiotic Lactobacillus GG effects on allergic sensitization and
asthma in infants at risk. Clin. Exp. Allergy 41, 1819–1821
(2011).
Article  CAS  PubMed  Google Scholar 
72. Herbst, T. et al. Dysregulation of allergic airway inflammation
in the absence of microbial colonization. Am. J. Respir. Crit.
Care Med. 184, 198–205 (2011).
Article  CAS  PubMed  Google Scholar 
73. Bisgaard, H. et al. Reduced diversity of the intestinal
microbiota during infancy is associated with increased risk of
allergic disease at school age. J. Allergy Clin. Immunol. 128,
646–652 (2011).
Article  PubMed  Google Scholar 
74. Domachowske, J. B., Dyer, K. D., Bonville, C. A. & Rosenberg,
H. F. Recombinant human eosinophil-derived neurotoxin/
RNase 2 functions as an effective antiviral agent against
respiratory syncytial virus. J. Infect. Dis. 177, 1458–1464
(1998). This is the first paper to propose a role for
eosinophils in antiviral host defence.
Article  CAS  PubMed  Google Scholar 
75. Adamko, D. J., Yost, B. L., Gleich, G. J., Fryer, A. D. &
Jacoby, D. B. Ovalbumin sensitization changes the
inflammatory response to subsequent parainfluenza infection.
Eosinophils mediate airway hyperresponsiveness, M2
muscarinic receptor dysfunction, and antiviral effects. J. Exp.
Med. 190, 1465–1478 (1999).


Article  CAS  PubMed  PubMed Central  Google Scholar 
76. Phipps, S. et al. Eosinophils contribute to innate antiviral
immunity and promote clearance of respiratory syncytial
virus. Blood 110, 1578–1586 (2007).
Article  CAS  PubMed  Google Scholar 
77. Davoine, F. et al. Virus-induced eosinophil mediator release
requires antigen-presenting and CD4+ T cells. J. Allergy Clin.
Immunol. 122, 69–77 (2008).
Article  CAS  PubMed  Google Scholar 
78. Dyer, K. D., Percopo, C. M., Fischer, E. R., Gabryszewski, S. J.
& Rosenberg, H. F. Pneumoviruses infect eosinophils and
elicit MyD88-dependent release of chemoattractant cytokines
and interleukin-6. Blood 114, 2649–2656 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
79. Skiest, D. J. & Keiser, P. Clinical significance of eosinophilia
in HIV-infected individuals. Am. J. Med. 102, 449–453
(1997).
Article  CAS  PubMed  Google Scholar 
80. Manetti, R. et al. CD30 expression by CD8+ T cells
producting type 2 helper cytokines. Evidence for large
numbers of CD8+CD30+ T cell clones in human
immunodeficiency virus infection. J. Exp. Med. 180, 2407–
2411 (1994).
Article  CAS  PubMed  Google Scholar 
81. Empson, M., Bishop, G. A., Nightingale, B. & Garsia, R. Atopy,
anergic status, and cytokine expression in HIV-infected
subjects. J. Allergy Clin. Immunol. 103, 833–842 (1999).
Article  CAS  PubMed  Google Scholar 
82. Rugeles, M. T. et al. Ribonuclease is partly responsible for the


HIV-1 inhibitory effect activated by HLA alloantigen
recognition. AIDS 17, 481–486 (2003).
Article  CAS  PubMed  Google Scholar 
83. Bochner, B. S. et al. Workshop report from the National
Institutes of Health Taskforce on the Research Needs of
Eosinophil-Associated Diseases (TREAD). J. Allergy Clin.
Immunol. 130, 587–596 (2012).
Article  PubMed  PubMed Central  Google Scholar 
84. Bochner, B. S. & Gleich, G. J. What targeting eosinophils has
taught us about their role in diseases. J. Allergy Clin. Immunol.
126, 16–25 (2010).
Article  CAS  PubMed  PubMed Central  Google Scholar 
85. Foster, P. S., Rosenberg, H. F., Asquith, K. L. & Kumar, R. K.
Targeting eosinophils in asthma. Curr. Mol. Med. 8, 585–590
(2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
86. Flood-Page, P. et al. Anti-IL-5 treatment reduces deposition of
ECM proteins in the bronchial subepithelial basement
membrane of mild atopic asthmatics. J. Clin. Invest. 112,
1029–1036 (2003).
Article  CAS  PubMed  PubMed Central  Google Scholar 
87. Menzies-Gow, A. et al. Anti-IL-5 (mepolizumab) therapy
induces bone marrow eosinophil maturational arrest and
decreases eosinophil progenitors in the bronchial mucosa of
atopic asthmatics. J. Allergy Clin. Immunol. 111, 714–719
(2003).
Article  CAS  PubMed  Google Scholar 
88. Leckie, M. J. et al. Effects of an interleukin-5 blocking
monoclonal antibody on eosinophils, airway hyper-
responsiveness, and the late asthmatic response. Lancet 356,


2144–2148 (2000).
Article  CAS  PubMed  Google Scholar 
89. Flood-Page, P. et al. A study to evaluate safety and efficacy of
mepolizumab in patients with moderate persistent asthma.
Am. J. Respir. Crit. Care Med. 176, 1062–1071 (2007).
Article  CAS  PubMed  Google Scholar 
90. Gibson, P. G. Inflammatory phenotypes in adult asthma:
clinical applications. Clin. Respir. J. 3, 198–206 (2009).
Article  PubMed  Google Scholar 
91. Anderson, G. P. Endotyping asthma: new insights into key
pathogenic mechanisms in a complex, heterogeneous disease.
Lancet 372, 1107–1109 (2008).
Article  PubMed  Google Scholar 
92. Nair, P. et al. Mepolizumab for prednisone-dependent asthma
with sputum eosinophilia. N. Engl. J. Med. 360, 985–993
(2009).
Article  CAS  PubMed  Google Scholar 
93. Haldar, P. et al. Mepolizumab and exacerbations of refractory
eosinophilic asthma. N. Engl. J. Med. 360, 973–984 (2009).
References 92 and 93 were the first two manuscripts to
document a significant role for eosinophils in the
pathogenesis of a specific asthma phenotype; patients
were stratified for disease activity.
Article  CAS  PubMed  PubMed Central  Google Scholar 
94. Castro, M. et al. Reslizumab for poorly controlled,
eosinophilic asthma: a randomized, placebo-controlled study.
Am. J. Respir. Crit. Care Med. 184, 1125–1132 (2011).
Article  CAS  PubMed  Google Scholar 


95. Pavord, I. D. et al. Mepoliuzmab for severe eosinophilic
asthma (DREAM): a multicenter, double-blind, placebo-
controlled trial. Lancet 380, 651–659 (2012).
Article  CAS  PubMed  Google Scholar 
96. Molfino, N. A., Gossage, D., Kolbeck, R., Parker, J. M. & Geba,
G. P. Molecular and clinical rationale for therapeutic
targeting of interleukin-5 and its receptor. Clin. Exp. Allergy
42, 712–737 (2012).
Article  CAS  PubMed  Google Scholar 
97. Corren, J. et al. Lebrikizumab treatment in adults with
asthma. N. Engl. J. Med. 365, 1088–1098 (2011).
Article  CAS  PubMed  Google Scholar 
98. Furuta, G. T. Eosinophilic esophagitis: update on
clinicopathological manifestations and pathophysiology. Curr.
Opin. Gastroenterol. 27, 383–388 (2011).
Article  PubMed  Google Scholar 
99. Mueller, S., Aigner, T., Neureiter, D. & Stolte, M. Eosinophil
infiltration and degranulation in oesophageal mucosa from
adult patients with eosinophilic oesophagitis: a retrospective
and comparative study on pathological biopsy. J. Clin. Pathol.
59, 1175–1180 (2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
100. Blanchard, C. et al. Eotaxin-3 and a uniquely conserved gene-
expression profile in eosinophilic esophagitis. J. Clin. Invest.
116, 536–547 (2006). In this study, the authors found that
CCL26 was the most highly induced gene in an extensive
study of oesophageal tissue from patients with
eosinophilic oesophagitis.
Article  CAS  PubMed  PubMed Central  Google Scholar 
101. Sherrill, J. D. et al. Variants of thymic stromal lymphopoietin


and its receptor associate with eosinophilic esophagitis. J.
Allergy Clin. Immunol. 126, 160–165 (2010).
Article  CAS  PubMed  PubMed Central  Google Scholar 
102. Mishra, A., Schlotman, J., Wang, M. & Rothenberg, M. E.
Critical role for adaptive T cell immunity in experimental
eosinophilic esophagitis in mice. J. Leukoc. Biol. 81, 916–924
(2007).
Article  CAS  PubMed  Google Scholar 
103. Rayapudi, M. et al. Indoor insect allergens are potent inducers
of experimental eosinophilic esophagitis in mice. J. Leukoc.
Biol. 88, 337–346 (2010).
Article  CAS  PubMed  PubMed Central  Google Scholar 
104. Rubinstein, E. et al. Siglec-F inhibition reduces esophageal
eosinophilia and angiogenesis in a mouse model of
eosinophilic esophagitis. J. Pediatr. Gastroenterol. Nutr. 53,
409–416 (2011).
Article  PubMed  PubMed Central  Google Scholar 
105. Zuo, L. et al. IL-13 induces esophageal remodeling and gene
expression by an eosinophil-independent, IL-13Rα2-inhibited
pathway. J. Immunol. 185, 660–669 (2010).
Article  CAS  PubMed  Google Scholar 
106. Lucendo, A. J., De Rezende, L., Comas, C., Caballero, T. &
Bellón, T. Treatment with topical steroids downregulates IL-5,
eotaxin-1/CCL11, and eotaxin-3/CCL26 gene expression in
eosinophilic esophagitis. Am. J. Gastroenterol. 103, 2184–
2193 (2008).
Article  CAS  PubMed  Google Scholar 
107. Straumann, A. et al. Anti-interleukin-5 antibody treatment
(mepolizumab) in active eosinophilic oesophagitis: a
randomised, placebo-controlled, double-blind trial. Gut 59,


21–30 (2010).
Article  CAS  PubMed  Google Scholar 
108. Assa'ad, A. H. et al. An antibody against IL-5 reduces numbers
of esophageal intraepithelial eosinophils in children with
eosinophilic esophagitis. Gastroenterology 141, 1593–1604
(2011).
Article  CAS  PubMed  Google Scholar 
109. Conus, S., Straumann, A., Bettler, E. & Simon, H. U.
Mepolizumab does not alter levels of eosinophils, T cells, and
mast cells in the duodenal mucosa in eosinophilic esophagitis.
J. Allergy Clin. Immunol. 126, 175–177 (2010).
Article  CAS  PubMed  Google Scholar 
110. Varga, J. & Kahari, V. M. Eosinophilia–myalgia syndrome,
eosinophilic fasciitis, and related fibrosing disorders. Curr.
Opin. Rheumatol. 9, 562–570 (1997).
Article  CAS  PubMed  Google Scholar 
111. Krahn, M. et al. CAPN3 mutations in patients with idiopathic
eosinophilic myositis. Ann. Neurol. 59, 905–911 (2006).
Article  CAS  PubMed  Google Scholar 
112. Kramerova, I., Kudryashova, E., Tidball, J. G. & Spencer, M.
J. Null mutation of calpain 3 (p94) in mice causes abnormal
sarcomere formation in vivo and in vitro. Hum. Mol. Genet. 13,
1373–1388 (2004).
Article  CAS  PubMed  Google Scholar 
113. Cools, J. et al. A tyrosine kinase created by fusion of the
PDGFRA and FIP1L1 genes as a therapeutic target of imatinib
in idiopathic hypereosinophilic syndrome. N. Engl. J. Med.
348, 1201–1214 (2003). This manuscript provided the first
evidence for the use of a receptor tyrosine kinase
inhibitor, imatinib, as a disease-directed therapy for a


specific variant of hypereosinophilic syndrome.
Article  CAS  PubMed  Google Scholar 
114. Valent, P. et al. Pathogenesis and classification of eosinophil
disorders: a review of recent developments in the field. Expert
Rev. Hematol. 5, 157–176 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
115. Cools, J. et al. The EOL-1 cell line as an in vitro model for the
study of FIP1L1-PDGFRA-positive chronic eosinophilic
leukemia. Blood 103, 2802–2805 (2004).
Article  CAS  PubMed  Google Scholar 
116. Stover, E. H. et al. Activation of FIP1L1–PDGFRα requires
disruption of the juxtamembrane domain of PDGFRα and is
FIP1L1-independent. Proc. Natl Acad. Sci. USA 103, 8078–
8083 (2006).
Article  CAS  PubMed  PubMed Central  Google Scholar 
117. Roufosse, F. et al. Mepolizumab as a corticosteroid-sparing
agent in lymphocytic variant hypereosinophilic syndrome. J.
Allergy Clin. Immunol. 126, 828–835 (2010).
Article  CAS  PubMed  PubMed Central  Google Scholar 
118. Ogbogu, P. U. et al. Hypereosinophilic syndrome: a
multicenter, retrospective analysis of clinical characteristics
and response to therapy. J. Allergy Clin. Immunol. 124, 1319–
1325 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
119. Valent, P. et al. Contemporary consensus proposal on criteria
and classification of eosinophilic disorders and related
syndromes. J. Allergy Clin. Immunol. 130, 607–612 (2012).
Article  PubMed  PubMed Central  Google Scholar 


120. Cools, J. et al. PKC412 overcomes resistance to imatinib in a
murine model of FIP1L1–PDGFRα-induced myeloproliferative
disease. Cancer Cell 3, 459–469 (2003).
Article  CAS  PubMed  Google Scholar 
121. Yamada, Y., Cancelas, J. A. & Rothenberg, M. E. Murine
model of hypereosinophilic syndromes/chronic eosinophilic
leukemia. Int. Arch. Allergy Immunol. 149 (Suppl. 1), 102–107
(2009).
Article  CAS  PubMed  Google Scholar 
122. Häcker, H., Chi, L., Rehg, J. E. & Redecke, V. NIK prevents
the development of hypereosinophilic syndrome-like disease
in mice independent of IKKα activation. J. Immunol. 188,
4602–4610 (2012).
Article  CAS  PubMed  Google Scholar 
123. Pease, J. E. & Williams, T. J. Eotaxin and asthma. Curr. Opin.
Pharmacol. 1, 248–253 (2001).
Article  CAS  PubMed  Google Scholar 
124. Takatsu, K., Kouro, T. & Nagai, Y. Interleukin-5 in the link
between innate and acquired immune response. Adv.
Immunol. 101, 191–236 (2009).
Article  CAS  PubMed  Google Scholar 
125. Wechsler, M. E. et al. Novel targeted therapies for
eosinophilic disorders. J. Allergy Clin. Immunol. 130, 563–571
(2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
126. Lloyd, C. M. & Rankin, S. M. Chemokines in allergic airway
disease. Curr. Opin. Pharmacol. 3, 443–448 (2003).
Article  CAS  PubMed  PubMed Central  Google Scholar 


127. Bochner, B. S. Siglec-8 on human eosinophils and mast cells,
and Siglec-F on murine eosinophils, are functionally related
inhibitory receptors. Clin. Exp. Allergy 39, 317–324 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
128. Kiwamoto, T., Kawasaki, N., Paulson, J. C. & Bochner, B. S.
Siglec-8 as a drugable target to treat eosinophil and mast cell-
associated conditions. Pharmacol. Ther. 135, 327–336 (2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
129. Hudson, S. A., Bovin, N. V., Schnaar, R. L., Crocker, P. R. &
Bochner, B. S. Eosinophil-selective binding and proapoptotic
effect in vitro of a synthetic Siglec-8 ligand, polymeric 6′-
sulfated sialyl Lewis X. J. Pharmacol. Exp. Ther. 330, 608–612
(2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
130. Kvarnhammar, A. M. & Cardell, L. O. Pattern recognition
receptors in human eosinophils. Immunology 136, 11–20
(2012).
Article  CAS  PubMed  PubMed Central  Google Scholar 
131. Månsson, A. & Cardell, L. O. Role of atopic status in Toll-like
receptor (TLR)7- and TLR9-mediated activation of human
eosinophils. J. Leukoc. Biol. 85, 719–727 (2009).
Article  CAS  PubMed  Google Scholar 
132. Ackerman, S. J. & Bochner, B. S. Mechanisms of eosinophilia
in the pathogenesis of hypereosinophilic disorders. Immunol.
Allergy Clin. North Am. 27, 357–375 (2007).
Article  PubMed  PubMed Central  Google Scholar 
133. Bedi, R., Du, J., Sharma, A. K., Gomes, I. & Ackerman, S. J.
Human C/EBP-ε activator and repressor isoforms
differentially reprogram myeloid lineage commitment and
differentiation. Blood 113, 317–327 (2009).


Article  CAS  PubMed  PubMed Central  Google Scholar 
134. Mori, Y. et al. Identification of the human eosinophil lineage-
committed progenitor: revision of phenotypic definition of
the human common myeloid progenitor. J. Exp. Med. 206,
183–193 (2009). In this study, the authors define the cell-
surface antigen profile of a fully committed eosinophil
progenitor in human bone marrow.
Article  CAS  PubMed  PubMed Central  Google Scholar 
135. Iwasaki, H. et al. Identification of eosinophil lineage-
committed progenitors in the murine bone marrow. J. Exp.
Med. 201, 1891–1897 (2005).
Article  CAS  PubMed  PubMed Central  Google Scholar 
136. Southam, D. S. et al. Increased eosinophil-lineage committed
progenitors in the lung of allergen-challenged mice. J. Allergy
Clin. Immunol. 115, 95–102 (2005).
Article  CAS  PubMed  Google Scholar 
137. Busse, W. W., Ring, J., Huss-Marp, J. & Kahn, J. E. A review
of treatment with mepolizumab, an anti-IL-5 mAb, in
hypereosinophilic syndromes and asthma. J. Allergy Clin.
Immunol. 125, 803–813 (2010).
Article  CAS  PubMed  Google Scholar 
138. Foster, P., Hogan, S., Ramsay, A., Matthaei, K. & Young, I.
Interleukin-5 deficiency abolishes eosinophilia, airways
hyperreactivity, and lung damage in a mouse asthma model.
J. Exp. Med. 183, 195–201 (1996).
Article  CAS  PubMed  Google Scholar 
139. Humbles, A. A. et al. A critical role for eosinophils in allergic
airways remodeling. Science 305, 1776–1779 (2004).
Article  CAS  PubMed  Google Scholar 


140. Walsh, E. R. et al. Strain-specific requirement for eosinophils
in the recruitment of T cells to the lung during the
development of allergic asthma. J. Exp. Med. 205, 1285–1292
(2008).
Article  CAS  PubMed  PubMed Central  Google Scholar 
141. Hertzman, P. A. et al. Association of the eosinophilia–myalgia
syndrome with the ingestion of tryptophan. N. Engl. J. Med.
322, 869–873 (1990).
Article  CAS  PubMed  Google Scholar 
142. Mayeno, A. N. et al. Characterization of “peak E”, a novel
amino acid associated with eosinophilia–myalgia syndrome.
Science 250, 1707–1708 (1990).
Article  CAS  PubMed  Google Scholar 
143. Smith, M. J. & Garrett, R. H. A heretofore undisclosed crux of
eosinophilia–myalgia syndrome: compromised histamine
degradation. Inflamm. Res. 54, 435–450 (2005).
Article  CAS  PubMed  Google Scholar 
144. Okada, S. et al. Immunogenetic risk and protective factors for
development of L-tryptophan-associated eosinophilia–myalgia
syndrome and associated symptoms. Arthritis Rheum. 61,
1305–1311 (2009).
Article  CAS  PubMed  PubMed Central  Google Scholar 
145. Allen, J. A. Post-epidemic eosinophilia–myalgia syndrome
associated with L-tryptophan. Arthritis Rheum. 63, 3633–3639
(2011).
Article  CAS  PubMed  Google Scholar 
146. Haskell, M. D., Moy, J. N., Gleich, G. J. & Thomas, L. L.
Analysis of signaling events associated with activation of
neutrophil superoxide anion production by eosinophil granule
major basic protein. Blood 86, 4627–4637 (1995).


CAS  PubMed  Google Scholar 
147. Munitz, A. & Levi-Schaffer, F. Eosinophils: 'new' roles for 'old'
cells. Allergy 59, 268–275 (2004).
Article  CAS  PubMed  Google Scholar 
148. Dyer, K. D., Garcia-Crespo, K. E., Killoran, K. E. & Rosenberg,
H. F. Antigen profiles for the quantitative assessment of
eosinophils in mouse tissues by flow cytometry. J. Immunol.
Methods 369, 91–97 (2011).
Article  CAS  PubMed  PubMed Central  Google Scholar 
149. Meyerholz, D. K., Griffin, M. A., Castilow, E. M. & Varga, S.
M. Comparison of histochemical methods for murine
eosinophil detection in an RSV vaccine-enhanced
inflammation model. Toxicol. Pathol. 37, 249–255 (2009).
Article  PubMed  PubMed Central  Google Scholar 
150. Yamaguchi, Y. et al. Models of lineage switching in
hematopoietic development: a new myeloid-committed
eosinophil cell line (YJ) demonstrates trilineage potential.
Leukemia 12, 1430–1439 (1998).
Article  CAS  PubMed  Google Scholar 
151. Histoshi, Y. et al. Distribution of IL-5 receptor-positive B cells.
Expression of IL-5 receptor on Ly-1(CD5)+ B cells. J.
Immunol. 144, 4218–4225 (1990).
Google Scholar 
152. Wise, E. L., Bonner, K. T., William, T. J. & Pease, J. E. A
single nucleotide polymorphism in the CCR3 gene ablates
receptor export to the plasma membrane. J. Allergy Clin.
Immunol. 126, 150–157 (2010).
Article  CAS  PubMed  Google Scholar 
153. Willetts, L. et al. Immunodetection of occult eosinophils in


lung tissue biopsies may help predict survival in acute lung
injury. Respir. Res. 12, 116 (2011).
Article  PubMed  PubMed Central  Google Scholar 
154. Macias, M. P. et al. Identification of a new murine eosinophil
major basic protein (mMBP) gene: cloning and
characterization of mMBP-2. J. Leukoc. Biol. 67, 567–576
(2000).
Article  CAS  PubMed  Google Scholar 
155. Ito, W. et al. Hepatocyte growth factor suppresses production
of reactive oxygen species and release of eosinophil-derived
neurotoxin from human eosinophils. Int. Arch. Allergy
Immunol. 147, 331–337 (2008).
Article  CAS  PubMed  Google Scholar 
156. Ochkur, S. I. et al. The development of a sensitive and specific
ELISA for mouse eosinophil peroxidase: assessment of
eosinophil degranulation ex vivo and in models of human
disease. J. Immunol. Methods 375, 138–147 (2012).
Article  CAS  PubMed  Google Scholar 
157. Blyth, D. I., Wharton, T. F., Pedrick, M. S., Savage, T. J. &
Sanjar, S. Airway subepithelial fibrosis in a murine model of
atopic asthma: suppression by dexamethasone or anti-
interleukin-5 antibody. Am. J. Respir. Cell. Mol. Biol. 23, 241–
246 (2000).
Article  CAS  PubMed  Google Scholar 
158. Grimaldi, J. C. et al. Depletion of eosinophils in mice through
the use of antibodies specific for C-C chemokine receptor 3
(CCR3). J. Leukoc. Biol. 65, 846–853 (1999).
Article  CAS  PubMed  Google Scholar 
159. Song, D. J. et al. Anti-Siglec-F antibody reduces allergen-
induced eosinophilic inflammation and airway remodeling. J.


Immunol. 183, 5333–5341 (2009).
Article  CAS  PubMed  Google Scholar 
160. Dyer, K. D. et al. Functionally competent eosinophils
differentiated ex vivo in high purity from normal mouse bone
marrow. J. Immunol. 181, 4004–4009 (2008).
Article  CAS  PubMed  Google Scholar 
161. Kopf, M. et al. IL-5-deficient mice have a developmental
defect in CD5+ B-1 cells and lack eosinophilia but have
normal antibody and cytotoxic T cell responses. Immunity 4,
15–24 (1996). This is the first description of a mouse
model devoid of the eosinophilopoietic cytokine IL-5.
Article  CAS  PubMed  Google Scholar 
162. Yoshida, T. et al. Defective B-1 cell development and
impaired immunity against Angiostrongylus cantonensis in
IL-5Rα-deficient mice. Immunity 4, 483–494 (1996).
Article  CAS  PubMed  Google Scholar 
163. Dent, L. A., Strath, M., Mellor, A. L. & Sanderson, C. J.
Eosinophilia in transgenic mice expressing interleukin 5. J.
Exp. Med. 172, 1425–1431 (1990).
Article  CAS  PubMed  Google Scholar 
164. Lee, N. A. et al. Expression of IL-5 in thymocytes/ T cells
leads to the development of a massive eosinophilia,
extramedullary eosinophilopoiesis, and unique
histopathologies. J. Immunol. 158, 1332–1344 (1997).
CAS  PubMed  Google Scholar 
165. Rothenberg, M. E., MacLean, J. A., Pearlman, E., Luster, A. D.
& Leder, P. Targeted disruption of the chemokine eotaxin
partially reduces antigen-induced tissue eosinophilia. J. Exp.
Med. 185, 785–790 (1995).


Article  Google Scholar 
166. Pope, S. M. et al. Identification of a cooperative mechanism
involving interleukin-13 and eotaxin-2 in experimental
allergic lung inflammation. J. Biol. Chem. 280, 13952–13961
(2005).
Article  CAS  PubMed  Google Scholar 
167. Pope, S. M., Zimmermann, N., Stringer, K. F., Karow, M. L. &
Rothenberg, M. E. The eotaxin chemokines and CCR3 are
fundamental regulators of allergen-induced pulmonary
eosinophilia. J. Immunol. 175, 5341–5350 (2005).
Article  CAS  PubMed  Google Scholar 
168. Ochkur, S. I. et al. Coexpression of IL-5 and eotaxin-2 in mice
creates an eosinophil-dependent model of respiratory
inflammation with characteristics of severe asthma. J.
Immunol. 178, 7879–7889 (2007).
Article  CAS  PubMed  Google Scholar 
169. Humbles, A. A. et al. The murine CCR3 receptor regulates
both the role of eosinophils and mast cells in allergen-induced
airway inflammation and hyperresponsiveness. Proc. Natl
Acad. Sci. USA 99, 1479–1484 (2002).
Article  CAS  PubMed  PubMed Central  Google Scholar 
170. Zhang, M. et al. Defining the in vivo function of Siglec-F, a
CD33-related Siglec expressed on mouse eoisnophils. Blood
109, 4280–4287 (2007).
Article  CAS  PubMed  PubMed Central  Google Scholar 
171. Leckie, M. J. Anti-interleukin-5 monoclonal antibodies:
preclinical and clinical evidence in asthma models. Am. J.
Resp. Med. 2, 245–259 (2003).
Article  CAS  Google Scholar 


Download references
Acknowledgements
The authors thank R. Dreyfuss (Medical Arts Branch, Office of the
Director, US National Institutes of Health (NIH)) for photographic
images and E. R. Fischer (Research Technologies Section, Rocky
Mountain Laboratories, US National Institute of Allergy and
Infectious Diseases (NIAID), NIH) for preparing the transmission
electron micrograph of the mouse eosinophil. H.F.R. receives
funding from the NIAID Division of Intramural Research (grants
AI000941 and AI000943); P.S.F. receives funding from the National
Health and Medical Research Council of Australia and fellowship
support from the Harvard Club of Australia.
Author information
Authors and Affiliations
1. Laboratory of Allergic Diseases, National Institute of Allergy
and Infectious Diseases, National Institutes of Health,
Bethesda, 20892, Maryland, USA
Helene F. Rosenberg & Kimberly D. Dyer
2. Priority Research Centre for Asthma and Respiratory Diseases,
Kookaburra Way, Hunter Medical Research Institute and
School of Biomedical Sciences and Pharmacy, Faculty of
Health, University of Newcastle, Newcastle, 2300, NSW,
Australia
Paul S. Foster
Authors
1. Helene F. Rosenberg
View author publications


Search author on:PubMed Google Scholar
2. Kimberly D. Dyer
View author publications
Search author on:PubMed Google Scholar
3. Paul S. Foster
View author publications
Search author on:PubMed Google Scholar
Corresponding author
Correspondence to Helene F. Rosenberg.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Disorders associated with eosinophilia and/or eosinophil
accumulation in organs and tissues (PDF 100 kb)
Related links
Related links
FURTHER INFORMATION


Helene F. Rosenberg's homepage
Glossary
Innate lymphoid cells
Cells that produce cytokines typically attributed to T helper
cell subsets (for example, IL-5) but that have no rearranged
antigen-specific receptors.
Alarmin
A term used to describe endogenous molecules that interact
with pattern- recognition receptors and thereby signal
danger to the host. These molecules are typically released
from necrotic cells and complement the function of the
more familiar pathogen-associated molecular patterns.
Examples discussed in this Review include HMGB1 and
IL-33. Another name for an alarmin is a damage- or danger-
associated molecular pattern.
Cytolytic degranulation
A mechanism through which eosinophils lyse, thereby
releasing either free granule proteins or fully intact
granules. This renders the cells non-viable. Intact granules
released in this manner can respond to physiological
secretagogues.
Piecemeal degranulation
A mechanism through which eosinophils (as well as
basophils and mast cells) release specific mediators from
cytoplasmic granules by transporting them to the cell
surface in membrane-bound cytoplasmic vesicles. The
eosinophils remain viable and fully responsive to
subsequent stimuli.
Secretagogues


Substances that induce the secretion of another substance
from a cell or storage granule.
Promyelocyte
A cell in the bone marrow that has differentiated from a
haematopoietic stem cell and that will ultimately generate
mature granulocytes, including neutrophils, basophils and
eosinophils. A promyelocyte can be identified in bone
marrow smears as a relatively large cell with a full, non-
condensed nucleus and lineage-specific cytoplasmic
granules.
Common myeloid progenitors
(CMPs). In current models of haematopoiesis, the most
primitive cells are multipotent, self-renewing
haematopoietic stem cells. By definition, CMPs are the
subset of progenitor cells that are capable of generating all
myeloid cells (that is, monocytes, macrophages, dendritic
cells, erythrocytes, megakaryocytes, platelets, basophils,
eosinophils and neutrophils) under appropriate cytokine
stimulation, but that are no longer capable of generating
cells of the lymphoid lineages (such as B cells, T cells and
NK cells).
Granulocyte–macrophage progenitors
(GMPs). By definition, GMPs are the subset of progenitor
cells that are capable of generating monocytes,
macrophages and all granulocyte lineages (that is,
basophils, eosinophils and neutrophils), but not the other
lineages. However, as noted in the text, human eosinophils
are not derived from the cells currently identified as GMPs.
Alternatively activated macrophages
One of the major differences between these cells and
classically activated macrophages is that these macrophages
are not primed with IFN. Instead, alternatively activated
macrophages are stimulated by TH2-type cytokines (such as


IL-4 or IL-13) and present soluble antigens to T cells.
Alternatively activated macrophages release CCL17, CCL18,
CCL22, IL-10, TGF, YM1, YM2 and RELM, and they
characteristically function to promote the resolution of
inflammation.
Nurse cells
As used in this Review, this term refers to skeletal muscle
cells that have been infected with the larval forms of
Trichinella species parasites. A capillary network forms
around the nurse cells, which provides crucial support for
the parasites as they develop.
Neutrophil extracellular traps
(NETs). Fibrous networks that are released into the
extracellular environment by neutrophils. They are
composed mainly of DNA, but also contain proteins from
neutrophil granules. NETs act as a mesh that traps
microorganisms and exposes them to neutrophil-derived
effector molecules.
Rights and permissions
Reprints and permissions
About this article
Cite this article
Rosenberg, H., Dyer, K. & Foster, P. Eosinophils: changing
perspectives in health and disease. Nat Rev Immunol 13, 9–22
(2013). https://doi.org/10.1038/nri3341
Download citation
•  Published: 16 November 2012


•  Issue date: January 2013
•  DOI: https://doi.org/10.1038/nri3341
Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
•  Eosinophils preserve bone homeostasis by
inhibiting excessive osteoclast formation and
activity via eosinophil peroxidase
○  Darja Andreev
○  Katerina Kachler
○  Aline Bozec
Nature Communications (2024)
•  A single infusion of engineered long-lived and
multifunctional T cells confers durable remission
of asthma in mice
○  Gang Jin
○  Yanyan Liu
○  Min Peng
Nature Immunology (2024)


•  Neutrophil-to-lymphocyte ratio and monocyte-to-
eosinophil ratio as prognostic indicators for
advanced nasopharyngeal carcinoma
○  Maoyu Ye
○  Aijie Huang
○  Honghui Liu
European Archives of Oto-Rhino-Laryngology (2024)
•  The impact of helminth-induced immunity on
infection with bacteria or viruses
○  Hong Chen
○  Zengguo Cao
○  Xuemin Jin
Veterinary Research (2023)
•  Omics and imaging combinatorial approach
reveals butyrate-induced inflammatory effects in
the zebrafish gut
○  Adrià López Nadal
○  Jos Boekhorst
○  Sylvia Brugman
Animal Microbiome (2023)
 Access through your institution
Buy or subscribe
Advertisement
[image]
Explore content


•  Research articles
•  Reviews & Analysis
•  News & Comment
•  Videos
•  Current issue
•  Collections
•  Follow us on Facebook
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Aims & Scope
•  Journal Information
•  Editorial policies
•  About the Editors
•  Reviews Cross-Journal Editorial Team
•  Journal Credits
•  Editorial input and checks
•  Editorial Values Statement
•  Journal Metrics
•  Publishing model
•  Calendars
•  Conferences
•  Posters
•  Web Feeds
•  Contact
Publish with us
•  For Authors
•  For Referees


•  Submit manuscript
Search
Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Nature Reviews Immunology (Nat Rev Immunol)
ISSN 1474-1741 (online)
ISSN 1474-1733 (print)
nature.com sitemap
About Nature Portfolio
•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index


Publishing policies
•  Nature portfolio policies
•  Open access
Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content
Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India


•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies
•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


 Close
[image]
Sign up for the Nature Briefing newsletter — what matters in
science, free to your inbox daily.
Email address


Sign up
I agree my information will be processed in accordance with the
Nature and Springer Nature Limited Privacy Policy.
 Close
Get the most important science stories of the day, free in your
inbox. Sign up for Nature Briefing
[image]


